Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;78(2):184-92.
doi: 10.1016/j.jpsychores.2014.07.020. Epub 2014 Aug 7.

A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C

Marilyn Huckans  1 , Bret Fuller  2 , Viva Wheaton  3 , Sarah Jaehnert  3 , Carilyn Ellis  4 , Michael Kolessar  3 , Daniel Kriz  3 , Jeanne Renee Anderson  3 , Kristin Berggren  4 , Hannah Olavarria  5 , Anna W Sasaki  6 , Michael Chang  6 , Kenneth D Flora  7 , Jennifer M Loftis  8
Affiliations

A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C

Marilyn Huckans et al. J Psychosom Res. 2015 Feb.

Abstract

Objective: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV).

Methods: 33 HCV+ adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN+ Group). 31 HCV+ adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN- Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI).

Results: Compared with the IFN- Group, the IFN+ Group experienced significantly (p<0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN+ Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed.

Conclusions: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.

Keywords: Anxiety; Cognition; Depression; Fatigue; Hepatitis C; Interferon; Pain.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

The authors have no competing interests to declare.

Figures

Fig. 1
Fig. 1
Psychiatric symptom rating scale scores before, during and after interferon alpha-based antiviral therapy (IFN) for hepatitis C virus (HCV) infection (IFN+ Group, n = 33). Significant (p < 0.05) changes across visits were observed on the Beck Depression Inventory, Second Edition (BDI) Total, BDI Somatic Factor, BDI Cognitive Affective Factor, Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory-Pain Interference (BPI-PI); specifically, psychiatric symptoms increased at Visit 2 during IFN and then returned to near baseline levels at Visit 3 following IFN termination. Inset box illustrates that for individuals undergoing IFN for HCV (IFN+ Group), there were significant effects of sustained viral response (SVR) on fatigue (FSS), overall depression (BDI Total), and somatic depression (BDI Somatic Factor) scores. Participants who achieved an SVR (n= 19) reported less fatigue (p= 0.017), less overall depression (p = 0.038), and fewer somatic depressive symptoms (p = 0.028), as compared with those who did not achieve an SVR (n= 6).
See this image and copyright information in PMC

References

    1. Global Burden Of Hepatitis CWG. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20–29. http://dx.doi.org/10.1177/0091270003258669 [PubMed PMID: 14681338]. - DOI - PubMed
    1. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7:261–287. [PubMed PMID: 12691470]. - PubMed
    1. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669–689. http://dx.doi.org/10.1038/ajg.2012.48 [quiz 90, PubMed PMID: 22525303]. - DOI - PubMed
    1. Hauser P, Morasco BJ, Linke A, Bjornson D, Ruimy S, Matthews A, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics. 2009;50:500–505. http://dx.doi.org/10.1176/appi.psy.50.5.500 [PubMed PMID: 19855036; PubMed Central PMCID: PMC2987665]. - DOI - PMC - PubMed
    1. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 2013;158:114–123. [PubMed PMID: 23437439]. - PubMed

Publication types

MeSH terms

LinkOut - more resources